Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:14 PM
Ignite Modification Date:
2025-12-24 @ 4:14 PM
NCT ID:
NCT00531466
Eligibility Criteria:
Inclusion Criteria:
* Subjects who provide written informed consent.
* Male or female subjects aged 18 to 70 years.
* In the judgment of the Principal Investigator, able to comply with protocol requirements.
* Subjects willing and able to withdraw from other anti-spasmodic/muscle relaxant drugs for at least two weeks before randomization (including but not limited to baclofen, benzodiazepines, clonazepam, clonidine, dantrolene, diazepam, gabapentin, and tizanidine).
* Neurological level between C-4 and T-12 spinal cord levels.
* SCI duration of 6 or more months.
* Muscle tone sufficient to score at least two (2) on the Ashworth Scale for at least one of the following lower muscle groups: ankle plantar flexors (gastrocnemius), knee extensors (quadriceps), knee flexors (hamstrings) and/or hip adductors (adductors) and seven (7) for the most spastic limb.
* ASIA Impairment Scale Exam score of B, C or D.
* Female subjects of childbearing potential must be either surgically sterile or using an effective method of contraception.
* Female subjects of childbearing potential must have a negative urine pregnancy test at baseline (Study Day 0).
Exclusion Criteria:
* Subjects with a known hypersensitivity to lidocaine or non-steroidal analgesics.
* Subjects with clinically significant cardiovascular, pulmonary, endocrine, hepatic, renal, neurological, metabolic, or psychiatric disease.
* Any recent history of mental illness, drug addiction, recreational drug use, or alcoholism and/or any similar condition that the investigator feels should prohibit study participation.
* Any significant illness during the four weeks preceding Study Day 1.
* History of cancer or inflammatory arthritis of large joints.
* History of gastric or duodenal ulcer.
* Concurrent symptomatic urinary tract infections with fever.
* Severe physical injury, direct impact trauma, or neurological trauma within the last 6 months not including Spinal Cord Injury.
* ASIA Impairment Scale score of A or E.
* Uncontrolled hypertension or hypotension.
* Percussive tenderness of vertebral body or spinous process.
* Subjects with corrective surgery to or contracture of the measurable hip, knee, or ankle joints.
* Subjects known to be Hepatitis B or HIV positive.
* Female subjects who are pregnant or nursing.
* Subjects who have received an investigational drug within 30 days before Screening visit.
* Subjects with any documented episodes of seizures.
* Subjects requiring use of clinically relevant 2C19 or 2D6 inhibitors, or concomitant use of lidocaine.
* Use of rescue medication(s) within 48 hours of baseline procedures.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT00531466
Study Brief:
Protocol Section:
NCT00531466